HPTN 102/PURPOSE 3

Recruiting

18 years and older

Female

Phase 2

1 Location

Brief description of study

This study will test an experimental drug named Lenacapavir (LEN), also known as Sunlenca® for the prevention of HIV-1 infection. The other HIV and pre-exposure prophylaxis (PrEP) medication included in this study is F/TDF (brand name Truvada®) which contains emtricitabine (F) and tenofovir disoproxil fumarate (TDF). F/TDF is approved for PrEP for use in adults and adolescents weighing at least 35kg (about 77 pounds) by the FDA in United States. Lenacapavir (LEN) is currently approved by the Food and Drug Administration (FDA) in the United States, Health Canada in Canada, and the European Medicines Agency (EMA) in Europe for the treatment of human immunodeficiency virus (HIV) infection in heavily treatment experienced (HTE) adults with multi-drug resistant (MDR) HIV infection. LEN is currently not approved by FDA or other regulatory authorities for treatment in other HIV populations or for prevention of HIV. LEN is being studied in this study for possible use for prevention of HIV infection.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
HIV Negative
Age: 18 Years
Gender: Female

Updated on 01 Aug 2024. Study ID: 854195

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).